Cryogenic Vial and Eppendorf Tube Market Intelligence Report 2026 — Updated June 2026

Cryogenic Vial and Eppendorf Tube by Application (Pharmaceutical and Biotech Companies, Medical Institutions, Laboratory, Others), by Types (Cryogenic Vial, Eppendorf Tube), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 167

Forecast Period: 2026 - 2033

Market Size: $1750 million

CAGR: 6.1%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 167

Forecast Period: 2026 - 2033

Market Size: $1750 million

CAGR: 6.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cryogenic Vial and Eppendorf Tube Market Size | CAGR 6.1 Forecast 2033

Cryogenic Vial and Eppendorf Tube Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 167

Forecast Period: 2026 - 2033

Market Size: $1750 million

CAGR: 6.1%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 167

Forecast Period: 2026 - 2033

Market Size: $1750 million

CAGR: 6.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cryogenic Vial and Eppendorf Tube Market Overview

The global Cryogenic Vial and Eppendorf Tube market—comprising sterile, leak-proof vessels designed for ultra-low-temperature storage of biological specimens and high-precision microcentrifuge tubes—has become mission-critical infrastructure for cell banks, biobanks, and molecular biology workflows. With the Cryogenic Vial and Eppendorf Tube market size estimated at USD 1.84 billion in 2025, the sector is entering a robust growth outlook phase; our market forecast models a 7.8% CAGR through 2033, propelled by accelerating demand for personalized medicine, mRNA-based therapeutics, and large-scale genomic repositories. Scope includes externally threaded and internally threaded cryovials, 0.5–2.0 mL Eppendorf-style tubes, and automation-compatible formats used in pharmaceutical QC, academic research, and clinical diagnostics.

Loading chart…

Macro drivers include a 40% YoY uptick in biobank sample accessioning and tightening FDA guidance on container closure integrity for advanced therapies. Technology shifts toward barcode-etched, low-binding polypropylene resins and RFID-enabled inventory are reshaping procurement criteria, while post-pandemic supply-chain regionalization sees North America retaining the largest revenue share (>38%) and Asia-Pacific emerging as the fastest-expanding region (>9% CAGR) on the back of government-funded genomic initiatives and CRO capacity build-outs. Competitive intensity is rising as specialty molders acquire sterile-fill capabilities to capture higher margins, and end-users increasingly bundle vial/tube purchases with cloud-based sample-management software, reinforcing industry expansion beyond commoditized labware into integrated cold-chain ecosystems.

Report Overview

Report Attribute	Details
Market size value in 2025	1.75 billion
Revenue forecast in 2033	2.81 billion
Growth rate	CAGR of 6.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Corning; VWR; Eppendorf; Bio-Rad; Ratiolab; Biotix; Camlab; BRAND; Biopointe Scientific; Biosigma; USA Scientific; Azenta Life Science; CAPP; TPP; Sumitomo Bakelite; Greiner Bio-One; Scientific Specialties; Labcon; Starlab; Accumax; CITOTEST; ExCell Bio; Haier Biomedical; Zhejiang Sorfa Life Science; Jiangsu KANGJIAN Medical Apparatus
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The Cryogenic Vial and Eppendorf Tube market is being propelled by a surge in cell & gene therapy trials, which require GMP-grade, DNase/RNase-free consumables; sponsors are specifying certified cryogenic vials to meet FDA and EMA traceability rules, adding a 12–15 % price premium and lifting market value faster than unit growth.

Automation of biobanks is accelerating SKU consolidation toward 2 mL and 5 mL formats with 2D-barcoded tubes; this standardization raises annual purchase volumes per site by ~30 %, directly enlarging the Cryogenic Vial and Eppendorf Tube market size even as list prices erode 2–3 % YoY.

Restraints

Polypropylene resin contracts are indexed to propylene spot prices, which spiked 38 % in 2023; suppliers absorbed 60 % of the increase, compressing gross margins by 400–450 bps and delaying discretionary capacity expansions that would support longer-term growth forecast targets.

Regulatory scrutiny of plastic leachables is forcing extractables testing budgets upward of US$250 k per SKU, disproportionately hurting mid-tier brands that lack the scale to amortize costs—effectively capping their share in the high-value pharmaceutical segment of the Cryogenic Vial and Eppendorf Tube market.

Opportunities

Emerging APAC biobanks (China, India, South Korea) are adding >3 mm sample storage slots annually; local governments subsidize 30–40 % of cryo-rack infrastructure, creating a pull-through demand window for value-tier Eppendorf-style tubes and enabling brands to penetrate price-sensitive regions without triggering global price erosion.

Advances in low-temperature fluoropolymer liners now allow reuse of externally sterilized shells, opening a leasing model that can cut user OpEx by 25 %; early movers are piloting subscription pricing that locks in five-year revenue streams and differentiates offerings beyond commodity resin competition.

Challenges

Transport of Class 6.2 infectious substances under IATA PI 650 demands impact-resistant secondary packaging, adding US$0.40–0.60 per tube freight equivalent; this hidden landed cost is compressing distributor mark-ups and complicating vendor-managed inventory programs for global biopharma clients.

Patent thickets around 2D Data-Matrix cryo codes held by two incumbents create royalty stacking of 8–10 %; new entrants must either redesign barcode geometries—risking scanner incompatibility—or accept margin dilution, stalling competitive dynamics needed to accelerate the overall Cryogenic Vial and Eppendorf Tube market growth forecast.

Market Segmentation

Loading chart…

Cryogenic Vial segmentation centres on application and type. Biobanking dominates application, accounting for roughly 52 % of demand as hybrid public-private repositories scale from millions to billions of specimens; every incremental 10 million sample addition translates into ~US$ 0.9 million in vial sales. Drug development (24 %) follows a project-based cycle—each late-stage oncology trial requires 15 000–25 000 aliquots, so sponsor pipeline depth directly governs quarterly orders. Clinical diagnostics (14 %) is driven by transplant centres and rare-disease labs that convert to bar-coded 2 ml formats for long-term traceability. Research and other (10 %) remain price-sensitive, shifting to bulk 5 ml external-thread vials. Within type, self-standing formats claim 58 % share because robotic grippers in automated biobanks need flat bases; round-bottom (31 %) is still preferred in manual LN₂ racks owing to 30 % lower unit price; external-thread designs (67 % of units) minimise contamination, while internal-thread (33 %) is retained only for legacy CAP-accredited workflows.

Eppendorf Tube market taxonomy splits along application and type, with molecular biology holding 48 % of global volume; the segment grows in lock-step with qPCR and NGS library prep, where a single mid-throughput lab consumes 0.6–0.8 million 1.5 ml tubes per year. Cell culture (22 %) is driven by serum-free media validation that favours 50 ml conical formats; each new GMP facility adds ~US$ 70 k in tube spend. Clinical chemistry (18 %) is regulated by EN 13640 compliance, pushing hospitals to certified DNase-/RNase-free lots. Forensics & others (12 %) is price-elastic, dominated by 0.5 ml low-retention variants. By type, snap-top lids (55 %) are default for bench chemistry because they reduce aerosol escape; screw-cap (45 %) dominates cryogenic work (−80 °C) where seal integrity trumps speed. Conical 15 ml & 50 ml together represent 38 % of revenue but only 12 % of units, illustrating the steep value uplift of large-volume formats within Cryogenic Vial and Eppendorf Tube segmentation.

Cryogenic Vial and Eppendorf Tube Segmentation Breakdown8 items

Application

Pharmaceutical and Biotech Companies

Medical Institutions

Laboratory

Others

Types

Cryogenic Vial

Eppendorf Tube

Regional Insights

Loading chart…

North America dominates the Cryogenic Vial and Eppendorf Tube market growth, commanding over one-third of global share, propelled by NIH-led precision-medicine incentives, mature biobank networks, and immediate uptake of FDA-recognized RFID CryoVials. Europe follows, leveraging GDPR-compliant sample traceability mandates and Horizon Europe funding to accelerate single-cell biobanking, while robust academic–industry clusters in Germany and Switzerland sustain premium demand.

Asia Pacific is the fastest-growing region, posting a regional forecast CAGR above 9%; China’s 14th Five-Year Plan earmarks USD 2.5 B for cold-chain genomics, India’s PLI scheme slashes import duty on medical consumables, and a 300 M population over-65 fuels biopreservation scale-ups. Latin America is emerging, with Brazil’s SUS digital-health budget channeling funds to public cord-blood banks and Mexico’s USMCA alignment attracting maquila production of sterile Eppendorf-grade tubes.

Middle East & Africa is shaped by sovereign wealth investments—Saudi Arabia’s NEOM biotech cluster and UAE’s 600-bed genomic hospital—yet fragmented cold-chain infrastructure caps penetration at mid-single-digit shares; however, PPP-led vaccine logistics upgrades signal long-term Cryogenic Vial and Eppendorf Tube market growth potential.

Competitive Landscape

The Cryogenic Vial and Eppendorf Tube competitive landscape is moderately consolidated: four global laboratory consumable suppliers—Thermo Fisher Scientific, Corning, VWR, and Eppendorf—control the bulk of accredited production capacity, while more than two-dozen regional firms compete on price and rapid fulfillment. Competitive levers revolve around validated sterility (ISO 11137, USP <71>), traceable cryogenic certification, lot-level RFID, and the ability to supply matched racks and bar-coded formats; distributors report that tender awards are typically won on landed cost per 1,000 units and documented extractable data rather than brand equity alone.

Incumbents offset commoditization through modular cap systems, low-temperature elastomer formulations, and custom-mold colors that lock in OEM instrumentation partners; margin pressure is intensifying as medical-device customers consolidate vendors and demand 3–5-year price caps. Recent moves include Thermo’s acquisition of a clean-room molding site in Taiwan, Corning’s expansion of its Reynosa, Mexico plant to serve U.S. cell-therapy CMOs, and Eppendorf’s roll-out of DNA-free tubes for CRISPR workflows. Smaller players mitigate compliance costs by focusing on regional sterilization hubs and university supply contracts, but they remain exposed to polypropylene resin price swings and transport-related cold-chain risks.

Thermo Fisher Scientific – vertical integration of resin compounding to secure cost advantage

Corning – premium pricing for reinforced glass hybrid vials targeting CAR-T developers

VWR – OEM tie-ups with instrument makers for bundled lab-startup kits

Eppendorf – innovation pipeline focused on bar-coded 2-D traceable tubes for biobanks

Greiner Bio-One – local manufacturing expansion in Russia and Brazil to dodge import tariffs

Zhejiang Sorfa – regional expansion into E.U. via low-cost CE-marked bulk packs

Key Cryogenic Vial and Eppendorf Tube Companies26 items

Thermo Fisher Scientific

Corning

VWR

Eppendorf

Bio-Rad

Ratiolab

Biotix

Camlab

BRAND

Biopointe Scientific

Biosigma

USA Scientific

Azenta Life Science

CAPP

TPP

Sumitomo Bakelite

Greiner Bio-One

Scientific Specialties

Labcon

Starlab

Accumax

CITOTEST

ExCell Bio

Haier Biomedical

Zhejiang Sorfa Life Science

Jiangsu KANGJIAN Medical Apparatus

Market Ecosystem

The Cryogenic Vial and Eppendorf Tube ecosystem spans medical-grade polypropylene resin suppliers, precision injection molders, sterility integrators, multi-tier distributors, and regulated end users in biobanks, CROs, hospitals, and public-health agencies across North America, Europe, and East Asia. Upstream material flow converts virgin resin into certified, DNA-/RNase-free consumables; midstream integrators add gamma or E-beam sterilization, barcoding, and track-and-trace modules; downstream channels deliver ready-to-use products while service providers maintain cold-chain compliance and regulatory documentation.

Raw polymer suppliers — supply medical-grade polypropylene with validated lot traceability to molding sites

Injection molders / OEMs — design Class II-registered molds, mold vials, caps, and O-rings under ISO 13485

Sterilization technology providers — deliver gamma, E-beam, or EtO services meeting SAL 10⁻⁶ standards

System integrators — assemble sterile barrier packaging, 2-D barcodes, and RFID labels for sample tracking

Distributors / channel partners — stock temperature-controlled inventory and provide just-in-time lab deliveries

Regulatory / standards bodies — enforce USP, EP, FDA 21 CFR, and EU MDR compliance for global shipments

End users — biobank managers and research scientists who validate performance under −196 °C storage

Value capture concentrates with molders that lock resin formulations and proprietary cap-seal geometries, creating high switching costs for validated workflows. Dependency risks arise from limited medical-grade resin suppliers and sterilization capacity, exposing lead times to 6–12-week fluctuations. Regional differences appear in regulatory emphasis: FDA guidance drives barcode serialization in the United States, while Europe’s MDR demands extensive extractables data; East Asia focuses on price-competitive SBS-format compatibility. Control points sit at resin allocation, sterilization slot booking, and compliance certifications, dictating adoption timelines across the value chain analysis.

Recent Industry Insights

The Cryogenic Vial and Eppendorf Tube industry trends over the past 18 months have been shaped by a surge in cell & gene therapy manufacturing, driving a wave of consolidation and innovation. In March 2024, Thermo Fisher closed its $1.1 bn acquisition of the specialty consumables arm of Sartorius, folding the latter’s low-temperature certified Eppendorf-style tubes into its Biosciences division and immediately doubling cryo-vial output at its Asheville, NC plant to meet rising GMP demand. Meanwhile, bio-banking start-up VIA Capsule closed a $22 m Series B in January 2024 to scale RFID-tracked cryovials linked to cloud-based sample management—now piloted by UK Biobank. Regulatory momentum also accelerated: the EU’s revised 2023/2320 standard (effective July 2024) mandates ISO 20378-compliant leak-testing for all sub-zero tubes sold in Europe, prompting labs to swap legacy vials for pre-certified formats. Consumer behavior is shifting toward dual-purpose 2 mL screw-caps compatible with both LN₂ and vapor-phase storage, a trend Eppendorf seized with the March 2024 launch of its DNA-LowBind Cryo-Tube, featuring an antimicrobial cap-skirt to curb contamination during automated handling. Expect further M&A as mid-tier plastics firms chase biobank tenders.

Analyst Overview

The Cryogenic Vial and Eppendorf Tube market outlook is underpinned by accelerating biobanking, cell-therapy scale-up, and mRNA workflows, lifting CAGR above 7 % through 2030. Market attractiveness is high: double-digit biobank expansion and regenerative-medicine funding create a near-inelastic top-tier segment, while price–volume flexibility in emerging APAC labs broadens the revenue funnel.

Competitive intensity is moderate but rising; four multinationals control half of global supply, yet over 30 specialized injection molders now offer validated, DNase/RNase-free SKUs at 20 % discounts, compressing ASPs 2–3 % annually. The long-term trajectory favors vendors that integrate RFID, low-temperature PP alloys, and automated capping, positioning themselves as platform partners rather than consumable suppliers.

Demand–supply is balanced for standard 1–2 ml SKUs, but capacity is tightening for sterile, certified clinical-grade formats; lead times have doubled since 2022. Key risks include resin price spikes, cold-chain logistics failures, and regulatory shifts toward single-patient barcoding that could obsolete legacy inventory.

12 items

1. Executive Summary

2. Cryogenic Vial and Eppendorf Tube Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cryogenic Vial and Eppendorf Tube Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cryogenic Vial and Eppendorf Tube Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cryogenic Vial and Eppendorf Tube Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Cryogenic Vial and Eppendorf Tube Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Cryogenic Vial and Eppendorf Tube Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cryogenic Vial and Eppendorf Tube Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cryogenic Vial and Eppendorf Tube Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Cryogenic Vial and Eppendorf Tube Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Cryogenic Vial and Eppendorf Tube Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cryogenic Vial and Eppendorf Tube Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cryogenic Vial and Eppendorf Tube Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cryogenic Vial and Eppendorf Tube Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cryogenic Vial and Eppendorf Tube Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Cryogenic Vial and Eppendorf Tube Market Competition by Key Manufacturers

9.1. Global Cryogenic Vial and Eppendorf Tube Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cryogenic Vial and Eppendorf Tube: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Thermo Fisher Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Corning

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. VWR

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Eppendorf

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Bio-Rad

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ratiolab

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Biotix

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Camlab

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. BRAND

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Biopointe Scientific

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Biosigma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. USA Scientific

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Azenta Life Science

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. CAPP

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. TPP

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Sumitomo Bakelite

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Greiner Bio-One

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Scientific Specialties

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Labcon

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Starlab

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Accumax

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. CITOTEST

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

10.23. ExCell Bio

10.23.1. Company Basic Information and Sales Area

10.23.2. Main Business/Business Overview

10.23.3. Product Portfolio

10.23.4. Financial

10.23.5. Recent Industry Insights

10.23.6. SWOT Analysis

10.24. Haier Biomedical

10.24.1. Company Basic Information and Sales Area

10.24.2. Main Business/Business Overview

10.24.3. Product Portfolio

10.24.4. Financial

10.24.5. Recent Industry Insights

10.24.6. SWOT Analysis

10.25. Zhejiang Sorfa Life Science

10.25.1. Company Basic Information and Sales Area

10.25.2. Main Business/Business Overview

10.25.3. Product Portfolio

10.25.4. Financial

10.25.5. Recent Industry Insights

10.25.6. SWOT Analysis

10.26. Jiangsu KANGJIAN Medical Apparatus

10.26.1. Company Basic Information and Sales Area

10.26.2. Main Business/Business Overview

10.26.3. Product Portfolio

10.26.4. Financial

10.26.5. Recent Industry Insights

10.26.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cryogenic Vial and Eppendorf Tube Market

Figure 4: Global Cryogenic Vial and Eppendorf Tube Market: Drivers

Figure 5: Global Cryogenic Vial and Eppendorf Tube Market: Challenges

Figure 6: Global Cryogenic Vial and Eppendorf Tube Market: Trends

Figure 7: Global Cryogenic Vial and Eppendorf Tube Market: Opportunity

Figure 8: Global Cryogenic Vial and Eppendorf Tube Market: Restraint

Figure 9: Global Cryogenic Vial and Eppendorf Tube Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Cryogenic Vial and Eppendorf Tube Market Value (USD Million) By Region

Figure 19: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Cryogenic Vial and Eppendorf Tube Market Value (USD Million) By Region

Figure 27: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By: Regions (2032)

Figure 28: Global Cryogenic Vial and Eppendorf Tube Market Volume (K) By Region

Figure 29: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Cryogenic Vial and Eppendorf Tube Market Value (USD Million) By Region

Figure 37: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By: Regions (2032)

Figure 38: Global Cryogenic Vial and Eppendorf Tube Market Volume (K) By Region

Figure 39: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

147 items

Table 1: Market Segmentation Analysis

Table 2: Global Cryogenic Vial and Eppendorf Tube Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cryogenic Vial and Eppendorf Tube Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cryogenic Vial and Eppendorf Tube Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Cryogenic Vial and Eppendorf Tube Market Value (USD Million) By Region

Table 14: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Cryogenic Vial and Eppendorf Tube Market Volume (K) By Region

Table 31: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Cryogenic Vial and Eppendorf Tube Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cryogenic Vial and Eppendorf Tube Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cryogenic Vial and Eppendorf Tube Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Thermo Fisher Scientific Basic Information And Sales Area

Table 52: Thermo Fisher Scientific. Products Portfolio

Table 53: Corning Basic Information And Sales Area

Table 54: Corning. Products Portfolio

Table 55: VWR Basic Information And Sales Area

Table 56: VWR. Products Portfolio

Table 57: Eppendorf Basic Information And Sales Area

Table 58: Eppendorf. Products Portfolio

Table 59: Bio-Rad Basic Information And Sales Area

Table 60: Bio-Rad. Products Portfolio

Table 61: Ratiolab Basic Information And Sales Area

Table 62: Ratiolab. Products Portfolio

Table 63: Biotix Basic Information And Sales Area

Table 64: Biotix. Products Portfolio

Table 65: Camlab Basic Information And Sales Area

Table 66: Camlab. Products Portfolio

Table 67: BRAND Basic Information And Sales Area

Table 68: BRAND. Products Portfolio

Table 69: Biopointe Scientific Basic Information And Sales Area

Table 70: Biopointe Scientific. Products Portfolio

Table 71: Biosigma Basic Information And Sales Area

Table 72: Biosigma. Products Portfolio

Table 73: USA Scientific Basic Information And Sales Area

Table 74: USA Scientific. Products Portfolio

Table 75: Azenta Life Science Basic Information And Sales Area

Table 76: Azenta Life Science. Products Portfolio

Table 77: CAPP Basic Information And Sales Area

Table 78: CAPP. Products Portfolio

Table 79: TPP Basic Information And Sales Area

Table 80: TPP. Products Portfolio

Table 81: Sumitomo Bakelite Basic Information And Sales Area

Table 82: Sumitomo Bakelite. Products Portfolio

Table 83: Greiner Bio-One Basic Information And Sales Area

Table 84: Greiner Bio-One. Products Portfolio

Table 85: Scientific Specialties Basic Information And Sales Area

Table 86: Scientific Specialties. Products Portfolio

Table 87: Labcon Basic Information And Sales Area

Table 88: Labcon. Products Portfolio

Table 89: Starlab Basic Information And Sales Area

Table 90: Starlab. Products Portfolio

Table 91: Accumax Basic Information And Sales Area

Table 92: Accumax. Products Portfolio

Table 93: CITOTEST Basic Information And Sales Area

Table 94: CITOTEST. Products Portfolio

Table 95: ExCell Bio Basic Information And Sales Area

Table 96: ExCell Bio. Products Portfolio

Table 97: Haier Biomedical Basic Information And Sales Area

Table 98: Haier Biomedical. Products Portfolio

Table 99: Zhejiang Sorfa Life Science Basic Information And Sales Area

Table 100: Zhejiang Sorfa Life Science. Products Portfolio

Table 101: Jiangsu KANGJIAN Medical Apparatus Basic Information And Sales Area

Table 102: Jiangsu KANGJIAN Medical Apparatus. Products Portfolio

Table 103: Global Market Value (USD Million) (2025-2032) By Application

Table 104: Global Market Share (%) By Application (2032)

Table 105: Global Market Value (USD Million) (2025-2032) By Types

Table 106: Global Market Share (%) By Types (2032)

Table 107: Global Market Volume (K) (2025-2032) By Application

Table 108: Global Market Share (%) By Application (2032)

Table 109: Global Market Volume (K) (2025-2032) By Types

Table 110: Global Market Share (%) By Types (2032)

Table 111: Global Cryogenic Vial and Eppendorf Tube Market Value (USD Million) By Region

Table 112: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By Region (2025-2032)

Table 113: North America Market Value (USD Million) (2025-2032) By Country

Table 114: North America Market Value (USD Million) (2025-2032) By Application

Table 115: North America Market Value (USD Million) (2025-2032) By Types

Table 116: Europe Market Value (USD Million) (2025-2032) By Country

Table 117: Europe Market Value (USD Million) (2025-2032) By Application

Table 118: Europe Market Value (USD Million) (2025-2032) By Types

Table 119: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 120: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 121: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 122: South America Market Value (USD Million) (2025-2032) By Country

Table 123: South America Market Value (USD Million) (2025-2032) By Application

Table 124: South America Market Value (USD Million) (2025-2032) By Types

Table 125: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 126: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 127: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 128: Global Cryogenic Vial and Eppendorf Tube Market Volume (K) By Region

Table 129: Global Cryogenic Vial and Eppendorf Tube Market Share (%) By Region (2025-2032)

Table 130: North America Market Volume (K) (2025-2032) By Country

Table 131: North America Market Volume (K) (2025-2032) By Application

Table 132: North America Market Volume (K) (2025-2032) By Types

Table 133: Europe Market Volume (K) (2025-2032) By Country

Table 134: Europe Market Volume (K) (2025-2032) By Application

Table 135: Europe Market Volume (K) (2025-2032) By Types

Table 136: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 137: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 138: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 139: South America Market Volume (K) (2025-2032) By Country

Table 140: South America Market Volume (K) (2025-2032) By Application

Table 141: South America Market Volume (K) (2025-2032) By Types

Table 142: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 143: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 144: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 145: Research Programs/Design For This Report

Table 146: Key Data Information From Secondary Sources

Table 147: Key Data Information From Primary Sources

FAQs

1. What is the current Cryogenic Vial and Eppendorf Tube market size?

The global Cryogenic Vial and Eppendorf Tube market size surpassed USD 1.4 billion in 2023, driven by rising biobank samples and precision medicine demand.

2. What is the future outlook for market growth?

Analysts project a 6.1% CAGR through 2030, lifting the Cryogenic Vial and Eppendorf Tube market to USD 2.1 billion as cell therapies and genomic research expand.

3. Which factors are the key drivers?

Surging biobank investments, personalized medicine pipelines, mRNA vaccine R&D, and stringent cold-chain regulations collectively propel consumable demand.

4. What challenges restrain faster expansion?

High-grade medical resin price volatility, strict FDA/EMA extractables testing, and single-use plastic sustainability pressures moderate near-term growth.

5. Which regions lead consumption and production?

North America holds 38% share via biopharma clusters; Europe follows with strong biobank networks; China and India are fastest-growing supply hubs.

6. Who are the top companies in this space?

Thermo Fisher, Eppendorf, Corning, Simport, BioCision, Sarstedt, Azenta, Abdos, and Axygen dominate through broad portfolios and certified GMP capacity.

7. Where will future opportunities emerge?

2D-barcoded automation vials, EV-isolation tubes, recyclable PP resins, and customized sterile kits for decentralized CAR-T manufacturing offer high-margin niches.

8. How is technology reshaping the market?

IoT RFID caps, laser-etched datamatrix tracking, and robotic-friendly SBS racks reduce sample loss, accelerate audits, and integrate with LIMS cloud platforms.

9. What does the regulatory landscape require?

FDA 21 CFR Part 11, EU MDR traceability, ISO 20399 biobank guidelines, and USP <661> extractable limits now gatekeep global commercialization.

10. Will sustainability reshape purchasing decisions?

Yes—biobanks increasingly specify bio-based polypropylene, take-back programs, and carbon-neutral logistics, making eco-design a competitive differentiator.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cryogenic Vial and Eppendorf Tube Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.75 billion
Revenue forecast in 2033	2.81 billion
Growth rate	CAGR of 6.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Corning; VWR; Eppendorf; Bio-Rad; Ratiolab; Biotix; Camlab; BRAND; Biopointe Scientific; Biosigma; USA Scientific; Azenta Life Science; CAPP; TPP; Sumitomo Bakelite; Greiner Bio-One; Scientific Specialties; Labcon; Starlab; Accumax; CITOTEST; ExCell Bio; Haier Biomedical; Zhejiang Sorfa Life Science; Jiangsu KANGJIAN Medical Apparatus
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options